Systematic reviews as a tool for planning and

interpreting trials by Bath, Philip M.W. & Gray, Laura J.
SYSTEMATIC REVIEWS AS A TOOL FOR PLANNING AND INTERPRETING TRIALS 
 
Philip MW Bath, MD, FRCP; Laura J Gray, MSc 
Stroke Trials Unit, University of Nottingham 
 
Correspondence: 
Professor Philip Bath 
Division of Stroke Medicine 
University of Nottingham 
City Hospital Campus 
Nottingham NG5 1PB UK 
 
Tel: +44 115 823 1768 
Fax: +44 115 823 1767 
Email: philip.bath@nottingham.ac.uk 
 
 
Abstract 
Background: Systematic reviews followed by a meta analysis are carried out in medical 
research to combine the results of two or more related studies. Stroke trials have 
struggled to show beneficial effects and meta-analysis should be used more widely 
throughout the research process to either speed up the development of useful 
interventions, or halt more quickly research with hazardous or ineffective interventions. 
 
Summary of review:This review summarises the clinical research process and illustrates 
how and when systematic reviews may be used throughout the development 
programme. Meta-analyses should be performed after observational studies, preclinical 
studies in experimental stroke, and after phase I, II and III clinical trials and phase IV 
clinical surveillance studies. Although meta-analyses most commonly work with summary 
dichotomous data, they may be performed to assess relationships between variables 
(meta-regression) and, ideally, should utilise individual patient data. Meta-analysis 
techniques may also work with ordered categorical outcome data (ordinal meta-analysis) 
and be used to perform indirect comparisons where original trial data do not exist. 
 
Conclusion:Systematic review/meta-analyses are powerful tools in medical research and 
should be used throughout the development of all stroke and other interventions. 
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Introduction 
Trials in acute stroke have struggled to identify effective interventions, the few successes 
including alteplase, aspirin, hemicraniectomy, and stroke units.1-5 In contrast, numerous 
interventions have been ineffective or even hazardous, including neuroprotectants and 
anticoagulants.6,7 Although there are many reasons to explain these failures, a central 
one is that most research programmes developing a new intervention do not analyse the 
results from their latest study in the context of existing data for that treatment. As a 
result, programmes often progress further than their existing data warrant. The 
techniques of systematic review and meta-analysis (quantitative systematic review) allow 
integration of data from separate but related sources. Meta-analyses may encompass 
data from observational studies, pre-clinical animal studies, or clinical human trials and 
should be integrated into the development plan of any new intervention (figure 1). 
 
Definition 
A systematic review is: ‘A summary of the medical literature that uses explicit methods 
to perform a thorough literature search and critical appraisal of individual studies and 
that uses appropriate statistical techniques to combine these valid studies’ 
(www.jr2.ox.ac.uk/bandolier/booth/diagnos/glossary.html). 
 
Doing a systematic review 
A standard sequence of events is necessary in performing a systematic review. The 
review needs a precise question; definition of which trials are to be included and 
excluded, and how these will be identified; what outcomes are to be collected; how 
numerical data will be integrated and analysed; and how the results will be interpreted. 
These decisions should be laid out in a protocol prior to performing the review itself, not 
least to prevent data-driven analyses and interpretations of the results. 
 
Systematic reviewing and meta-analysis are no different from any other scientific 
technique in that there are advantages and disadvantages, and strengths and 
weaknesses, in the process. So inadequate definition of the protocol, poor searching of 
suitable studies, publication bias (whereby neutral or negative trials remain unpublished 
and therefore cannot be found), poor trial quality, data driven analyses, selective 
reporting of outcomes, and biased interpretation of the results, can each damage the 
value of the review and even change its conclusions. 
 
Observational studies 
The basis for some candidate interventions can be derived from the results of 
observational studies. The results from such studies may be integrated using systematic 
review techniques to provide a summary estimate. For example, several small studies 
have reported that a high blood pressure during the acute phase of stroke is associated 
with a poor outcome; a meta-analysis subsequently confirmed this finding 8 and provides 
justification for studying the effect of lowering blood pressure, as several trials are now 
doing. 
 
Preclinical studies 
The development programme for most interventions starts with preclinical studies in 
experimental models of stroke followed by clinical studies. The decision to move from 
laboratory to the clinic is often made on the basis of a few positive animal studies 
without considering all the available experimental data (whether published or 
unpublished), some of which may be neutral or negative. A quantitative systematic 
review (including meta-analysis) of preclinical data should be performed prior to any 
decision to start clinical studies.9 The review should address explicitly the STAIR I criteria 
10 for experimental data, these including the effect of the intervention by dose, timing of 
administration, stroke model (transient, permanent), species (ideally including a 
primate), age and sex of animal, and presence of co-morbidities (hypertension, 
hyperlipidaemia, diabetes). Unfortunately, preclinical studies have not always antedated 
clinical trials. In one case, review of preclinical studies found that nimodipine was only 
mildly neuroprotective,11 this information becoming available after clinical studies had 
largely finished; unsurprisingly, a meta-analysis of the clinical trials was neutral.12 Such 
systematic reviews of preclinical work are useful for justifying the funding, whether 
commercial of academic, of clinical studies, as seen for nitric oxide in stroke 13 which 
underpins the ongoing MRC ENOS trial (www.enos.ac.uk/).14 The CAMARADES 
(http://www.camarades.info/) collaboration is coordinating the development of 
systematic reviews in preclinical stroke. Such systematic reviews can also identify 
potential problems in the design and conduct of preclinical studies.15 
 
Phase II clinical trials 
Conventionally, several randomised phase II trials are done to investigate the safety, 
tolerability, and feasibility of administration of a new intervention, and to identify suitable 
doses and potential mechanisms of action, and signals of potential efficacy based on 
surrogate measures. A systematic review of the clinical use of the intervention should be 
initiated at the beginning of phase II, this being updated as each phase II trial is 
completed. Whilst individual phase II trials are grossly underpowered to assess efficacy, 
systematic reviews based on several trials may show trends helpful for making further 
decisions on stopping or continuing the development programme. In this respect, it is 
questionable whether phase III trials of gavestinel would have been done if the results of 
a systematic review of phase II trials 6 had been published prior to the decision to 
proceed to formal studies of efficacy, these ultimately being neutral.16 In contrast, phase 
II trials of intravenous magnesium were promising 6 although the IMAGES phase III trial 
was unfortunately neutral.17 Similarly, phase II trials of abciximab suggested potential 
benefit 18,19 although this was not realised in a subsequent phase III trial.20 In these 
examples of magnesium and abciximab, although the phase III trials were ultimately 
neutral, the summary of phase II trials at least justified proceeding with further 
development. 
 
Phase III clinical trials and end of development 
Systematic reviews have two main roles once a phase III programme has been 
completed. Ideally, they will be used to sum up all the available data, as done with 
positive interventions such as aspirin (for acute ischaemic stroke 3) and dipyridamole (for 
secondary prevention 21) as well as neutral (e.g. lubeluzole 22) and negative (e.g. selfotel 
23) interventions. Systematic reviews of positive phase III trials will help regulatory 
approval, and can support changes in guidelines and, ultimately, medical practice. In 
other cases, systematic reviews will identify a strong trend justifying further trials, as 
with citicoline in acute stroke,24 or areas where further research is required with a proven 
intervention, e.g. potentially extending the time window for intravenous alteplase 1,2 from 
3 to 4.5 or even 6 hours, as being studied respectively in the ongoing ECASS III and IST-
3 trials.25 
 
The system of time-limited patents means that some drugs are incompletely studied 
although the available evidence, when integrated in a systematic review, suggests that 
further development might be warranted; there are several examples, one being 
pentoxifylline and related methylxanthine derivatives.26 Finally, it may become clear that 
development of a particular intervention could potentially have been curtailed earlier 
than happened; for example, the meta-analysis may suggest a neutral effect whilst other 
trials are underway, as seen with low molecular weight heparins.27,28 Worse, a signal of 
hazard may be present in the meta-analysis at a time when further trials are being 
designed (and subsequently take place), as occurred for tirilazad mesylate.29 These 
examples provide strong justification for performing cumulative meta-analyses which 
need to be updated after each and every phase II and III trial; figure 2 shows the 
cumulative meta-analysis for tirilazad. 
 
Phase IV studies 
The introduction of a new intervention into clinical practice may not be the end of 
research studies, particularly if the treatment is controversial, perhaps because of 
significant side effects. So-called phase IV post-marketing studies may be performed to 
assess safety and efficacy in the real world, and these may be integrated systematically. 
For example, although alteplase was shown to improve functional outcome in hyperacute 
ischaemic stroke and was subsequently licensed, concerns about routine use by 
inexperienced staff and the potential for causing fatal intracerebral haemorrhage meant 
that a number of phase IV studies were done. These were integrated in a systematic 
review 30 which showed that safety was adversely affected if the protocol for 
administering alteplase was violated. 
 
Individual patient data meta-analysis 
Most of the quantitative systematic reviews quoted above used summary (or group) data 
from each trial. However, access to data at the subject rather than trial level allows 
individual patient data meta-analyses to be performed. Such analyses are considered to 
be the ‘gold-standard’ 31 since they allow effects to be studied in subgroups of patients; 
for example, the addition of dipyridamole to aspirin is more effective in preventing stroke 
recurrence than aspirin alone across several trials irrespective of age, qualifying event 
(stroke or TIA) and history of hypertension.21 Additional subgroups may be calculated 
from the trial data, e.g. the effect of combined aspirin and dipyridamole relative to 
aspirin is constant across different baseline risk strata derived from the above baseline 
variables.21 Unfortunately, if summary meta-analyses are complicated by missing trial 
data, this problem is magnified in analyses based on individual patient data, especially in 
older studies where databases have been discarded or are incompatible with modern 
computers and statistical software. If a prospective systematic review is to be updated 
during the development of a new intervention (as recommended above) then there is 
every reason to base this on individual patient data (rather than summary data) to 
facilitate subgroup analyses and meta-regression (see below). 
 
An important example of a prospective individual patient meta-analysis is that describing 
the effect of early decompressive surgery for malignant infarction of the middle cerebral 
artery. Although surgery was known to reduce death, its effect on functional outcome 
was unclear and three trials were performed. The nature of the condition and 
intervention meant that any trial would be very small in size and its results unreliable; 
integration of the three data sets into a systematic review has confirmed the benefit of 
this intervention in carefully selected patients.5 
Meta-regression 
Summary data from trials are usually combined in one-dimension, that is by outcome. 
However, the relationship between outcome and potential modifying covariates can be 
assessed in two dimensions by plotting the variables in a scatter plot. These data may 
then be analysed using regression techniques to identify the mathematical relationship 
between the variables. A classic example in stroke is the curvilinear relationship between 
lowering blood pressure and stroke reduction in randomised controlled trials, these 
showing that greater blood pressure lowering leads to a larger reduction in subsequent 
stroke.32 In the arena of preclinical stroke, the effect of nitric oxide synthase inhibitors in 
transient models of experimental ischaemia appears to decline as the time between the 
onset of ischaemia and starting treatment increases (figure 3).33 Access to individual 
patient data facilitates meta-regression at the patient rather than trial level. As a result, 
the effect of one or more modulating variables on the relationship between the 
intervention and outcome can be studied in more detail. By example, the efficacy of 
thrombolysis falls as the stroke-needle time increases.2 
 
Indirect comparisons 
All of the analyses referred to above relied on direct comparative data. But, sometimes 
data comparing two interventions (e.g. ‘A’ versus ‘B’) may not be available although 
studies of each may have been performed against a third comparator (e.g. ‘A’ versus ‘C’, 
and ‘B’ versus ‘C’). In this case, indirect comparisons of the agents may be performed 
using network or other indirect comparison meta-analysis techniques.34 By example, the 
combination of aspirin and warfarin appears to be more effective than the combination of 
aspirin and clopidogrel in preventing thromboembolic stroke after acute coronary 
syndromes 35 while the combination of oestrogen and progesterone causes more venous 
thromboembolic events (but not stroke) than oestrogen alone when used as hormone 
replacement therapy (Sare, Gray & Bath, unpublished). 
 
Other uses of systematic review techniques 
Systematic review techniques may be used for more than just analysing the potential 
efficacy of interventions. For example, the failure of many trials and interventions in 
acute stroke raises the possibility that there may be better approaches to analysing trial 
data than currently used. The ‘Optimising Analysis of Stroke Trials’ (OAST) Collaboration 
has confirmed standard statistical lore, using individual patient data from stroke trials, 
that ordinal analyses of ordered categorical data (as exists in the modified Rankin Scale) 
are more efficient than those based on dichotomous data.36 Designing trials to use 
ordinal analyses (such as ordinal logistic regression) results in a 25-30% reduction in 
sample size although this advantage appears to depend on the type of intervention being 
studied (OAST Collaboration, unpublished data). 
 
In an extension to this concept, it is possible to generate ordered categorical outcomes 
for vascular prevention trials. For example, the binary outcome of ‘stroke/no stroke’ may 
be converted into the 5 levels of outcome, e.g. ‘fatal stroke/severe stroke/mild 
stroke/TIA/no event’. Using published outcome data from 80+ prevention trials, analysis 
of this ordinal data increased statistical power (or reduced sample size for a given power) 
as well as providing information on the effect of the interventions on stroke severity.37 
Importantly, ordered categorical data from trials may be meta-analysed in similar ways 
to binary data.38 
 
Conclusion 
The technique of systematic review, encompassing the numerical approach of meta-
analysis, is a powerful ally in the development of new stroke interventions. It can be 
used to combine results from related studies, whether from epidemiology, pre-clinical 
animal studies, phase II explanatory trials, phase III efficacy trials, or phase IV post-
marketing studies. It can also be used to help improve techniques for analysing and 
designing trials. Like any technique, systematic reviews have strengths and weaknesses, 
and the results may be misleading if the review is performed badly. Additionally, meta-
analyses may obtain the wrong answer even if performed well, but this is true of all 
scientific techniques. Systematic reviews are not a surrogate for performing adequate 
numbers of adequate-sized trials, but they will enhance the interpretation of trial data 
and its presentation to healthcare professionals and policy makers. It is reasonable to 
suggest that a systematic review should be performed (or updated) after each and every 
study in the development of a new intervention and doing so will enhance decision 
making when deciding whether to proceed with further development, and when 
implementing the positive findings for a new intervention. 
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FIGURE 2 
Cumulative meta-analysis plot for tirilazad versus control 
 
FIGURE 3 
Effect of delay until first dose in minutes on total infarct volume in experimental models 
of transient ischaemia.33 The size of the circle is proportional to the size of the study. 
 
